Malaria Diagnosis and Treatment

Introduction to Malaria

• Malaria is caused by six Plasmodium species that infect humans: P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, with P. falciparum being the most dangerous and the main cause of severe malaria, responsible for 90% of malaria deaths 1.

Malaria Symptoms and Diagnosis

• The symptoms of malaria are non-specific and include fever, headache, chills, nausea, vomiting, and diarrhea, with the presence of fever having a likelihood ratio of 5.1 for diagnosis, while its absence makes malaria unlikely (LR 0.12) 1.
• Common laboratory findings in malaria patients include mild anemia 2 and normal or mildly elevated white blood cell count 1.

Severe Malaria Criteria

• According to the World Health Organization (WHO) criteria, the presence of one or more of the following criteria indicates severe malaria: CNS involvement, cardiovascular shock, respiratory distress, renal failure, bleeding, severe anemia, acidosis, hyperlactatemia, hypoglycemia, hyperparasitemia, and jaundice 3.

Treatment of Uncomplicated Malaria

• The first-line treatment for uncomplicated P. falciparum malaria is artemisinin-based combination therapy (ACT), specifically artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DP) 4, 5.
• The dosing regimen for AL is 4 tablets at 0 and 8 hours on day 1, and then 4 tablets twice daily on days 2-3, while DP is dosed at 3 tablets daily for 3 days for patients weighing 36-75 kg, and 4 tablets daily for 3 days for patients weighing over 75 kg 4, 5.

Treatment of Severe Malaria

• Intravenous artesunate is the first-line treatment for all severe malaria cases, with a dosing regimen of 2.4 mg/kg at 0, 12, and 24 hours, and then daily until parasite density is less than 1% 4, 5.
• If intravenous artesunate is unavailable, intravenous quinine can be used as an alternative, with a loading dose of 20 mg salt/kg over 4 hours, followed by 10 mg/kg over 4 hours every 8 hours 5.

Pregnancy and Malaria Treatment

• Artemether-lumefantrine is safe for use in all trimesters of pregnancy, according to the WHO and CDC, with no association found between its use and congenital malformations or miscarriage in multiple trials 4, 5.

Common Pitfalls and Caveats

• It is essential to ensure adequate fat intake when administering AL to avoid subtherapeutic levels and treatment failure 4, 6, 5.
• Delayed diagnosis of P. falciparum malaria can significantly increase mortality, highlighting the importance of prompt diagnosis and treatment 5.
• Both AL and DP can cause QTc prolongation, and their use should be avoided in patients at risk or taking QTc-prolonging medications 4, 6, 5.
• G6PD testing is mandatory before administering primaquine or tafenoquine to prevent severe hemolysis in patients with G6PD deficiency 4, 6.

Liver Function Test Derangement in Malaria

Diagnosis and Clinical Presentation

• The World Health Organization (WHO) considers jaundice combined with parasitemia >100,000/mL (or >20,000/mL for P. knowlesi) as a criterion for severe malaria, indicating the need for intensive management 7
• The American Society of Tropical Medicine and Hygiene recommends checking baseline liver function tests (LFTs) in all malaria patients, including bilirubin, ALT, AST, alkaline phosphatase, and albumin, to rule out other causes of liver dysfunction, such as viral hepatitis and drug-induced liver injury 8

Treatment and Management

• The WHO and the Centers for Disease Control and Prevention (CDC) agree that LFT abnormalities are not a contraindication to artemisinin-based combination therapy or artesunate, and treatment should proceed immediately while investigating other potential causes of liver dysfunction 7, 8
• The European Society of Clinical Microbiology and Infectious Diseases recommends monitoring parasitemia every 12 hours until declining, then every 24 hours until negative, and repeating LFTs at day 3 and day 7 to document improvement and detect delayed transaminase elevation 8, 7

Clinical Implications and Monitoring

• The Lancet Gastroenterology and Hepatology suggests that if LFTs continue to deteriorate despite parasite clearance, alternative diagnoses such as drug-induced liver injury, ischemic hepatitis, or sepsis-associated cholestasis should be considered 8, 9

Management of Recurrent Malaria: Evidence‑Based Recommendations

Diagnosis and Species Identification

• Obtain thick and thin Giemsa‑stained blood smears immediately for any patient with recurrent malaria to identify the Plasmodium species and quantify parasitemia, which distinguishes treatment failure, hypnozoite relapse, or new reinfection. (World Health Organization criteria) 10

Uncomplicated Plasmodium falciparum Recurrence

• Treat uncomplicated recurrent P. falciparum with an artemisinin‑based combination therapy (ACT) – either artemether‑lumefantrine or dihydroartemisinin‑piperaquine – and ensure adequate dietary fat when using artemether‑lumefantrine to avoid sub‑therapeutic drug levels. (WHO malaria treatment guidelines) 10
• Monitor parasitemia every 12 hours until it falls below 1 %, then daily until the smear is negative. (WHO malaria treatment guidelines) 10

Severe Plasmodium falciparum Recurrence

• If any WHO severe‑malaria criterion is present, start intravenous artesunate 2.4 mg/kg at 0, 12, 24 hours and then once daily until parasitemia is <1 %, with admission to intensive care. (WHO severe malaria protocol) 10
• After three artesunate doses, switch to oral ACT once parasitemia is <1 % and the patient can tolerate oral medication. (WHO severe malaria protocol) 10
• When IV artesunate is unavailable, substitute intravenous quinine 20 mg/kg (salt) as a loading dose over 4 hours, followed by 10 mg/kg every 8 hours. (MMWR Recommendations) 11
• Perform delayed‑hemolysis surveillance on days 7, 14, 21, and 28 after artesunate therapy. (WHO post‑artesunate monitoring) 10

Relapse Prevention for Plasmodium vivax / P. ovale

• For recurrent P. vivax or P. ovale, give chloroquine (if the parasite is chloroquine‑sensitive) or an ACT, plus primaquine 15 mg daily for 14 days to eradicate liver hypnozoites, but only after confirming normal G6PD activity to avoid severe hemolysis. (WHO radical cure recommendations) 10
• Tafenoquine may be used as a single‑dose alternative to primaquine, also requiring G6PD testing beforehand. (WHO radical cure recommendations) 10
• Omitting primaquine (or tafenoquine) after a P. vivax/P. ovale episode leads to inevitable future relapses. (WHO radical cure recommendations) 10